- United States
- /
- Life Sciences
- /
- NasdaqGM:TKNO
Earnings Update: Here's Why Analysts Just Lifted Their Alpha Teknova, Inc. (NASDAQ:TKNO) Price Target To US$10.00
Alpha Teknova, Inc. (NASDAQ:TKNO) just released its quarterly report and things are looking bullish. Results overall were credible, with revenues arriving 2.2% better than analyst forecasts at US$10m. Higher revenues also resulted in lower statutory losses, which were US$0.08 per share, some 2.2% smaller than the analysts expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
Taking into account the latest results, the consensus forecast from Alpha Teknova's six analysts is for revenues of US$44.4m in 2026. This reflects a notable 12% improvement in revenue compared to the last 12 months. Losses are expected to hold steady at around US$0.34. Before this earnings announcement, the analysts had been modelling revenues of US$46.5m and losses of US$0.34 per share in 2026.
See our latest analysis for Alpha Teknova
The consensus price target rose 11% to US$10.00, seeming to imply that weaker revenue sentiment is not expected to have a major impact on the company's valuation. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Alpha Teknova, with the most bullish analyst valuing it at US$12.00 and the most bearish at US$8.00 per share. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. It's clear from the latest estimates that Alpha Teknova's rate of growth is expected to accelerate meaningfully, with the forecast 9.2% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 1.2% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 5.9% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Alpha Teknova to grow faster than the wider industry.
The Bottom Line
The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Regrettably, they also downgraded their revenue estimates, but the latest forecasts still imply the business will grow faster than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for Alpha Teknova going out to 2027, and you can see them free on our platform here..
Even so, be aware that Alpha Teknova is showing 2 warning signs in our investment analysis , you should know about...
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGM:TKNO
Alpha Teknova
Produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.
Adequate balance sheet and slightly overvalued.
Similar Companies
Market Insights
Community Narratives

